September 3, 2020
GlyCardial Diagnostics has been granted with a Digital Sandbox Programme Project
The aim of the Digital Sandbox Programme – Biobanks and Quality Reigsters funding is to support companies (startups and SMEs) requiring acces and collaboration with Biobanks, Sample Holders and Quality Reigsters in Europe, for the further development and/or commercialisation of new technologies, products or services.
The Apo J-Glyc Project is leaded by GlyCardial Diagnostics with the collaboration of some Sample Holders.
GlyCardial Diagnostics will use this EIT Health funding to develop a novel in vitro diagnostic test for the early detection cardiac events. This technology is based on the quantification of Apo J-Glyc in blood as a unique biomarker for the early diagnosis of cardiac ischemia and the prediction of patient’s evolution after an ischemic event.